Please login to the form below

Not currently logged in
Email:
Password:

risk-sharing agreements

This page shows the latest risk-sharing agreements news and features for those working in and with pharma, biotech and healthcare.

Friend or foe?

Friend or foe?

The first was about Express Scripts, a US pharmacy benefits manager, demanding risk-sharing price arrangements from pharma companies. ... In more sophisticated examples, the uncertainty that each side faces is mitigated by risk-sharing agreements.

Latest news

  • Pharma industry must listen to pharmacies Pharma industry must listen to pharmacies

    This is especially true given that risk-sharing agreements could potentially see companies lose money, Dr Alessi acknowledged.

  • Emerging business models for pharma Emerging business models for pharma

    The precursors to such networks are well-established ideas like joint ventures, outsourcing relationships and risk-sharing agreements, but pharma holobionts appear to evolving well beyond these relatively primitive arrangements in ... Cultures vary

  • Model behaviour in proactive and reactive pharma markets Model behaviour in proactive and reactive pharma markets

    health technology assessments, risk-sharing and real-world evidence (RWE). ... Companies should also continue to propose outcome-based agreements (OBA), despite risk-sharing having become mostly about discounting and fallen into the Trough of

  • Just des(s)erts - choices for payers in times of austerity

    AIFA has in the past rewarded innovation with high prices, while controlling expenditure through risk-sharing agreements. ... However, it appears that the true savings from risk-sharing agreements are far less than anticipated, because refunds are

  • Industry 'should work closer with payers on drug development'

    felt that the sector should absorb more risk to improve biopharmaceutical agents and the public health. ... agreeing that risk-sharing agreements between biopharmaceutical companies and payers would lead to more innovative and effective therapies.

More from news
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Market access improvements in Turkey Market access improvements in Turkey

    Such models are already found in several European countries and indeed worldwide, and are generally known as managed entry or risk-sharing agreements.

  • Pharma–payer partnerships – rhetoric or reality? Pharma–payer partnerships – rhetoric or reality?

    Payer partnerships fall into two categories: price and reimbursement (risk-sharing agreements/patient access schemes) and value add (provision of services beyond the pill). ... more value to the industry than to payers (Raftery J, BMJ 2010; 340:c1672

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics